{"product_id":"gerresheimer-bcg-matrix","title":"Gerresheimer Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGerresheimer’s BCG Matrix peels back the curtain on which product lines are driving growth, which are funding the business, and which are dragging it down. This snapshot hints at strategic moves, but the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and editable Word + Excel files to act on immediately. Purchase the complete report to skip the guesswork and plan your next moves with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-fillable syringes (RTF)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologics reached about USD 420 billion in 2024 and global pre-fillable syringe (PFS) demand was roughly USD 5.2 billion, driving strong uptake of Gerresheimer’s ready-to-fill formats that combine scale and pharma-grade quality. High switching costs plus regulatory file transfers and device validations create durable share protection. Continued investment in capacity, quality systems and customer onboarding will defend leadership and let RTFs mature into cash cows as growth normalizes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuto-injectors and pens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelf-administration is mainstream in specialty meds, and Gerresheimer’s auto-injectors and pens sit in the Stars quadrant as device programs win sticky, high-value contracts; service components now often exceed 20% of deal value (2024 industry benchmarks). The mix skews to higher ASPs and recurring services, supporting premium margins. Double down on innovation, human factors, and lifecycle upgrades to remain first-in-line for new molecules, and keep service teams synchronized with pharma launch calendars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced sterile vials (ready-to-use)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvanced sterile vials (ready-to-use) cut fill-finish risk and are high-demand Stars in the \u0026gt;$400bn global biologics market in 2024, making them attractive to CDMOs and pharma. Premium pricing and validated supply chains protect Gerresheimer share and margins. Prioritize investment in capacity, secondary packaging and sterilization technology. Maintain rigorous compliance to keep rivals out.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-performance glass (low-defect, coated)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-performance borosilicate vials with anti-delamination coatings and tight specs reduce breakage and delamination, critical for injectables; 2024 production runs reported measurable drops in rejects and faster regulatory audits for leading suppliers. Ongoing capex into furnace upgrades and inline inspection preserves this quality moat in a growing injectable glass segment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElite borosilicate\u003c\/li\u003e\n\u003cli\u003eCoatings cut delamination\u003c\/li\u003e\n\u003cli\u003eTight specs lower rejects\u003c\/li\u003e\n\u003cli\u003eCapex: furnace + inline inspection\u003c\/li\u003e\n\u003cli\u003e2024: smoother regulatory audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInhalation devices (DPIs\/MDIs platforms)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic respiratory demand remains high—WHO reports ~262 million people with asthma and ~251 million with COPD (2019), underpinning steady inhaler volume; reformulations for low-global-warming-potential propellants add momentum for DPIs\/MDIs platforms. Platform devices with proven reliability anchor major accounts; prioritize sustainability redesigns and fast-track validations to stay the default when portfolios switch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh prevalence: asthma 262M, COPD 251M (WHO 2019)\u003c\/li\u003e\n\u003cli\u003eFocus: green propellants and fast validation\u003c\/li\u003e\n\u003cli\u003eStrategy: sustain reliability to retain large accounts\u003c\/li\u003e\n\u003cli\u003eGoal: remain default supplier during portfolio transitions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-to-fill PFS, auto-injectors chase \u003cstrong\u003eUSD 420bn\u003c\/strong\u003e biologics market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer’s Stars: ready-to-fill formats and auto-injectors capture 2024 biologics tailwinds (global biologics ~USD 420bn; PFS demand ~USD 5.2bn) with high switching costs and services \u0026gt;20% of deal value, driving premium margins. Invest in capacity, human factors and sterilization tech to convert Stars to future cash cows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eKey action\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReady-to-fill PFS\u003c\/td\u003e\n\u003ctd\u003eUSD 5.2bn demand\u003c\/td\u003e\n\u003ctd\u003eCapex + quality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuto-injectors\u003c\/td\u003e\n\u003ctd\u003eServices \u0026gt;20% deal value\u003c\/td\u003e\n\u003ctd\u003eHFE + lifecycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile vials\u003c\/td\u003e\n\u003ctd\u003eBiologics USD 420bn\u003c\/td\u003e\n\u003ctd\u003eSterilization tech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix review of Gerresheimer's portfolio, with strategic moves for Stars, Cash Cows, Question Marks and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Gerresheimer BCG Matrix placing each business unit in a quadrant for quick strategy clarity and action\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard vials and ampoules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard vials and ampoules are a mature, massive and stable cash cow for Gerresheimer, underpinning roughly €1.5bn group sales in 2024 and generating steady free cash flow. Scale drives cost leadership and margin resilience; keeping OEE high and scrap low is critical, with incremental line upgrades typically paying back in under 18 months. Maintain price discipline over promotional spend to protect cash conversion and EBITDA contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma plastic bottles (HDPE\/PET)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTC and Rx oral solids keep HDPE\/PET bottle lines humming in a low-growth market (approx. 1–3% annual growth), delivering predictable volumes and long contracts typically 3–7 years. Efficient molds and scale drive gross margins; lightweighting initiatives can reduce material use by up to 15–20% and widen margins. Minimal selling is required as volumes are contract-backed and repeatable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosmetic glass packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBranded beauty is steady with repeat SKUs and reliable reorders that stabilize demand; maintaining furnace utilization above 90% converts fixed costs into cash when production runs full. Optimize SKU mix toward premium finishes, which can command a 20–30% price premium, and tighten batch planning to reduce changeover losses. Protect long-term customer relationships and avoid overspending on short-lived novelty runs that dilute margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDroppers, closures, and accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDroppers, closures, and accessories bundle naturally with primary containers, supporting Gerresheimer’s focus on integrated solutions; the global pharma closures market showed low-single-digit growth in 2024 while exhibiting high repeat demand from existing customers.\u003c\/p\u003e\n\u003cp\u003eStandardize components and cut SKU complexity to lower OPEX and inventory; prioritize milking the installed base with tight quality controls to protect margin and compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: low-growth, high-repeat\u003c\/li\u003e\n\u003cli\u003eTag: standardize-SKU\u003c\/li\u003e\n\u003cli\u003eTag: bundle-with-containers\u003c\/li\u003e\n\u003cli\u003eTag: milk-installed-base\u003c\/li\u003e\n\u003cli\u003eTag: quality-first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy device components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy device components act as Gerresheimer cash cows, providing stable revenue—accounting for roughly 30% of product sales in 2024—and supporting corporate cash flow; tooling is largely amortized and unit-level margins remain healthy, near mid-teen EBITDA for these lines. Maintain tooling and QA, avoid major redesigns, and harvest cash to fund higher-growth bets in drug delivery and specialty glass.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue: ~30% of 2024 sales\u003c\/li\u003e\n\u003cli\u003eMargins: mid-teens EBITDA on legacy lines\u003c\/li\u003e\n\u003cli\u003eCapex: minimal for tooling upkeep\u003c\/li\u003e\n\u003cli\u003eStrategy: maintain QA\/tooling, harvest funds, reinvest in growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e€1.5bn\u003c\/strong\u003e vials, \u003cstrong\u003e15-20%\u003c\/strong\u003e cut, beauty \u003cstrong\u003e+20-30%\u003c\/strong\u003e premium\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStandard vials\/ampoules: ~€1.5bn sales 2024, high margins, payback \u0026lt;18m.\u003c\/p\u003e\n\u003cp\u003eOral solids\/HDPE: 1–3% growth, lightweighting saves 15–20% material.\u003c\/p\u003e\n\u003cp\u003eBranded beauty: \u0026gt;90% utilization, premium +20–30% price.\u003c\/p\u003e\n\u003cp\u003eLegacy devices: ~30% product sales, mid-teens EBITDA, low capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVials\u003c\/td\u003e\n\u003ctd\u003e€1.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy\u003c\/td\u003e\n\u003ctd\u003e30% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eGerresheimer BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Gerresheimer BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no demo placeholders—just a fully formatted, analysis-ready report built for strategic clarity. Once bought, the final document is delivered immediately and is ready to edit, print, or present to your team or clients. Crafted by strategy experts, it slots straight into your planning and decision-making without surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUndifferentiated commodity glass SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhen specifications are generic and rivals undercut, margins evaporate and unit gross margins for undifferentiated glass SKUs frequently compress to single digits. High volumes do not restore low price realization, so Gerresheimer should exit tail SKUs or consolidate tooling to cut complexity. Redeploy freed capacity toward differentiated, higher-value vial and cartridge runs to protect margin and utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume custom vanity projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-off low-volume vanity projects drain engineering hours and force frequent line changeovers, reducing throughput and raising per-unit costs. Cash returns rarely match the complexity and operational disruption, so trim SKUs or shift retained items to premium pricing to cover costs. Implement stricter go\/no-go gates and say no more often to protect core margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging device variants with declining programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnd-of-life platforms limp along supplying service parts and tie up inventory: industry studies show legacy SKUs can be ~70% of SKU count but generate \u0026lt;20% of revenue, driving inventory carrying costs of roughly 15–25% annually. Plan clear sunset schedules, bundle last-time-buys to capture residual demand and reduce small-batch headaches. Redeploy tooling where ROI \u0026gt; payback threshold or scrap decisively to cut holding costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice-capped tenders with strict lowest-bid wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrice-capped tenders with strict lowest-bid wins are classic Dogs for Gerresheimer: they soak up manufacturing capacity for thin, often single-digit margins, leaving little room for quality-led upsell and compromising average selling prices (ASPs). Avoid participating unless lines are idle or the contract is strategically essential to retain a key customer; passing preserves ASPs and protects premium portfolio segments. Monitor utilization and margin floors closely in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eTags: capacity-drain\u003c\/li\u003e\n\u003cli\u003eTags: margin-compression\u003c\/li\u003e\n\u003cli\u003eTags: avoid-unless-idle\u003c\/li\u003e\n\u003cli\u003eTags: protect-ASPs\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-engineered features buyers won’t pay for\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOver-engineered features that procurement won't fund become Dogs for Gerresheimer; in 2024 Gerresheimer reported group sales of €1.9bn, so non-revenue features that add cost risk margin pressure and reduced ROI. Extra steps slow throughput and raise per-unit costs, hurting margins and delivery times. Remove or repackage as optional modules, keeping the core simple and profitable.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: core profitable SKUs\u003c\/li\u003e\n\u003cli\u003eOptional add-ons: shift cost to buyer\u003c\/li\u003e\n\u003cli\u003eThroughput: eliminate extra steps\u003c\/li\u003e\n\u003cli\u003eMeasure: track contribution margin per SKU\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunset \u003cstrong\u003e70%\u003c\/strong\u003e legacy SKUs: stop dogs, redeploy capacity, lift margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs are low‑margin, commoditized SKUs that compress gross margins to single digits and drain capacity. Legacy SKUs (~70% of SKUs) generate \u0026lt;20% of revenue and push inventory carrying costs to ~15–25% annually. With 2024 group sales €1.9bn, exit or consolidate tail SKUs, redeploy tooling to vials\/cartridges, enforce strict go\/no‑go gates and premium pricing for retained items.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (undiff SKUs)\u003c\/td\u003e\n\u003ctd\u003eSingle‑digit %\u003c\/td\u003e\n\u003ctd\u003eExit\/price up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy SKU share\u003c\/td\u003e\n\u003ctd\u003e~70% of SKUs; \u0026lt;20% revenue\u003c\/td\u003e\n\u003ctd\u003eSunset\/scrap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory cost\u003c\/td\u003e\n\u003ctd\u003e~15–25% pa\u003c\/td\u003e\n\u003ctd\u003eReduce SKUs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003ctd\u003eRedeploy capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolymer syringes and vials (COP\/COC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolymer syringes and vials (COP\/COC) are a strong fit for sensitive biologics—2024 adoption sits near 20% of parenteral primary packaging versus ~80% glass, with polymer prefilled-syringe demand growing ~10% CAGR outlook to 2029. High growth potential for Gerresheimer warrants investing in stability proofs and big-pharma validations; if pull-through stalls, narrow indications and refocus commercial efforts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnected drug delivery (smart caps, sensors)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConnected drug delivery targets a huge pain point—US medication nonadherence costs an estimated 100–300 billion dollars annually—so smart caps and sensors that have shown adherence uplifts of up to ~20% in trials are strategically attractive. Standards and payer reimbursement remained unsettled in 2024, so expect cash burn pre-scale; pilot with top customers and prove outcomes. Double down if reimbursement materializes; divest if engagement stays weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable packaging lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSustainable packaging lines face rising 2024 regulatory and brand pressure, while customer willingness to pay remains mixed; early wins (recyclable caps, mono-materials) can cascade into mandatory specs. Build recyclable options and LCA proof points to capture value and document CO2 savings. If margins lag, position sustainable SKUs as add-ons rather than core until cost parity or premium realization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract assembly\/CDMO device services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContract assembly\/CDMO device services are a Question Mark for Gerresheimer: pharma outsourcing drives a global CDMO market ~160 billion USD in 2024 with ~8% CAGR, offering big upside, but the field is crowded and requires heavy QA\/regulatory investment; Gerresheimer holds low share today while demand grows. Winning lighthouse programs to secure multiyear contracts is critical—either invest in cleanrooms and throughput or remain a niche specialist.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: ~160B USD (2024), ~8% CAGR\u003c\/li\u003e\n\u003cli\u003eStatus: Low share, high-growth\u003c\/li\u003e\n\u003cli\u003eStrategy: Win lighthouse programs\u003c\/li\u003e\n\u003cli\u003eOptions: Scale cleanrooms\/throughput or niche\u003c\/li\u003e\n\u003cli\u003eRisk: Intense competition, heavy QA costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen inhalers for new propellants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNext‑gen inhalers for low‑GWP propellants sit in Question Marks as market shifts toward green propellants accelerate but timing remains uneven across regions; pMDIs still represent roughly half of global inhaler units in 2024.\u003c\/p\u003e\n\u003cp\u003eTechnical and validation risks persist, with regulatory pathways and stability data required before scale; co‑development with anchor clients can secure initial wins.\u003c\/p\u003e\n\u003cp\u003eIf standards drift away from the platform, pivot platform learnings into existing HFA devices to capture near‑term revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: pMDIs ~50% of units (2024); uneven regulatory timelines\u003c\/li\u003e\n\u003cli\u003eRisk: tech validation, stability testing, and regulatory approval hurdles\u003c\/li\u003e\n\u003cli\u003eAction: co‑develop with anchor clients for first wins; pivot learnings to legacy devices if standards change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolymer PFS \u003cstrong\u003e20%\u003c\/strong\u003e, \u003cstrong\u003e10%\u003c\/strong\u003e CAGR; CDMO \u003cstrong\u003e160B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolymer PFS\/vials: ~20% polymer share (2024) vs ~80% glass; polymer PFS demand ~10% CAGR to 2029 — invest in stability\/validation or narrow focus. Connected delivery: US nonadherence USD100–300B; trials show up to ~20% adherence uplift — pilot and prove outcomes. CDMO\/prefill: market ~160B USD (2024), ~8% CAGR; win lighthouse contracts or remain niche.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolymer PFS\u003c\/td\u003e\n\u003ctd\u003e20% share\u003c\/td\u003e\n\u003ctd\u003e~10% CAGR\u003c\/td\u003e\n\u003ctd\u003evalidation\u003c\/td\u003e\n\u003ctd\u003einvest\/validate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eoutcome-dependent\u003c\/td\u003e\n\u003ctd\u003ereimbursement\u003c\/td\u003e\n\u003ctd\u003epilot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e160B USD\u003c\/td\u003e\n\u003ctd\u003e~8% CAGR\u003c\/td\u003e\n\u003ctd\u003ecompetition\u003c\/td\u003e\n\u003ctd\u003esecure lighthouses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097919623516,"sku":"gerresheimer-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/gerresheimer-bcg-matrix.png?v=1781795209","url":"https:\/\/pestel-analysis.com\/products\/gerresheimer-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}